Biodegradable and non-biodegradable drug-eluting stents and bare metal stents in acute myocardial infarction
10.3969/j.issn.2095-4344.2014.34.007
- VernacularTitle:可降解与不可降解药物涂层支架及裸金属支架置入治疗急性心肌梗死
- Author:
Zhen YANG
- Publication Type:Journal Article
- Keywords:
myocardial infarction;
angioplasty;
coronary restenosis
- From:
Chinese Journal of Tissue Engineering Research
2014;(34):5449-5454
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Large randomized controled clinical trials have shown that drug-eluting stents has a lower
restenosis rate compared with bare-metal stents, but the drug-eluting stents cannot reduce major cardiovascular events and death rates, and long-term folow-up of clinical registries show the drug-eluting stents even may
increase late stent thrombosis events.
OBJECTIVE:To evaluate the incidence of stenosis and adverse reactions after treatment with biodegradable, non-biodegradable drug-eluting stents and bare-metal stents in patients after myocardial infarction.
METHODS:We retrospectively analyzed the clinical data of 236 cases of acute myocardial infarction, in which 79 cases were treated with biodegradable sirolimus-eluting stents, 83 cases treated with non-biodegradable
sirolimus-eluting stents, and 74 cases treated with bare metal stents. Then, we compared late lumen loss and restenosis within 12 months after stent implantation and major adverse cardiac reactions within 24 months after stent implantation.
RESULTS AND CONCLUSION: After 12 months, the late lumen loss of the bare stent group was significantly higher than that of biodegradable and non-biodegradable sirolimus-eluting stent groups (P < 0.05), but the
difference in stent restenosis rate (P > 0.05). After 24 months, there were no differences in death, cardiac death, recurrent myocardial infarction, target vessel revascularization, target lesion revascularization, major adverse
cardiac events and stent thrombosis events among the three groups. These three kinds of stents need to be
further studied in their long-term efficacy and safety as percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
